Sarepta Therapeutics (Brazil) Performance
| S1RP34 Stock | BRL 31.35 0.72 2.35% |
The entity has a beta of 0.35, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, Sarepta Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Sarepta Therapeutics is expected to be smaller as well. At this point, Sarepta Therapeutics has a negative expected return of -0.37%. Please make sure to validate Sarepta Therapeutics' maximum drawdown, skewness, daily balance of power, as well as the relationship between the potential upside and kurtosis , to decide if Sarepta Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Sarepta Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in April 2025. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
| Begin Period Cash Flow | 1.5 B | |
| Total Cashflows From Investing Activities | 495.4 M |
Sarepta |
Sarepta Therapeutics Relative Risk vs. Return Landscape
If you would invest 4,008 in Sarepta Therapeutics on December 2, 2024 and sell it today you would lose (873.00) from holding Sarepta Therapeutics or give up 21.78% of portfolio value over 90 days. Sarepta Therapeutics is generating negative expected returns and assumes 2.2148% volatility on return distribution over the 90 days horizon. Simply put, 19% of stocks are less volatile than Sarepta, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Sarepta Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Sarepta Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Sarepta Therapeutics, and traders can use it to determine the average amount a Sarepta Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1675
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | S1RP34 |
Estimated Market Risk
| 2.21 actual daily | 19 81% of assets are more volatile |
Expected Return
| -0.37 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.17 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Sarepta Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Sarepta Therapeutics by adding Sarepta Therapeutics to a well-diversified portfolio.
Sarepta Therapeutics Fundamentals Growth
Sarepta Stock prices reflect investors' perceptions of the future prospects and financial health of Sarepta Therapeutics, and Sarepta Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Sarepta Stock performance.
| Return On Equity | -1.59 | |||
| Return On Asset | -0.11 | |||
| Profit Margin | (0.82) % | |||
| Operating Margin | (0.61) % | |||
| Current Valuation | 56.41 B | |||
| Shares Outstanding | 1.76 B | |||
| Price To Book | 25.76 X | |||
| Price To Sales | 67.46 X | |||
| Revenue | 701.89 M | |||
| EBITDA | (317.41 M) | |||
| Cash And Equivalents | 1.74 B | |||
| Cash Per Share | 21.78 X | |||
| Total Debt | 1.1 B | |||
| Debt To Equity | 2.19 % | |||
| Book Value Per Share | 4.91 X | |||
| Cash Flow From Operations | (443.17 M) | |||
| Earnings Per Share | (22.24) X | |||
| Total Asset | 3.15 B | |||
About Sarepta Therapeutics Performance
By analyzing Sarepta Therapeutics' fundamental ratios, stakeholders can gain valuable insights into Sarepta Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Sarepta Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Sarepta Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. Sarepta Therapeutics, Inc. was incorporated in 1980 and is headquartered in Cambridge, Massachusetts. SAREPTA THERDRN operates under Biotechnology classification in Brazil and is traded on Sao Paolo Stock Exchange. It employs 866 people.Things to note about Sarepta Therapeutics performance evaluation
Checking the ongoing alerts about Sarepta Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Sarepta Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Sarepta Therapeutics generated a negative expected return over the last 90 days | |
| The company reported the revenue of 701.89 M. Net Loss for the year was (418.78 M) with loss before overhead, payroll, taxes, and interest of (165.84 M). | |
| Sarepta Therapeutics has accumulated about 1.74 B in cash with (443.17 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 21.78. |
- Analyzing Sarepta Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Sarepta Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Sarepta Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Sarepta Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Sarepta Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Sarepta Therapeutics' stock. These opinions can provide insight into Sarepta Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Sarepta Stock analysis
When running Sarepta Therapeutics' price analysis, check to measure Sarepta Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sarepta Therapeutics is operating at the current time. Most of Sarepta Therapeutics' value examination focuses on studying past and present price action to predict the probability of Sarepta Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sarepta Therapeutics' price. Additionally, you may evaluate how the addition of Sarepta Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA |